PMC8077504_01
History chart of ePROs as reported from the patient on her mobile device during treatment with vemurafenib. Blue, well-being; dark red, rash; light red, hand-foot syndrome; yellow, loss of appetite; olive green, nausea; orange, headache; green, cold symptoms; light purple, sensory disturbance; dark purple, gait disorder.
cro-0014-0616-g01.jpg
PMC8077504_01_cro-0014-0616-g01.jpg
F1
At the same time the patient was using an electronic diary (Consilium CareTM) for shared reporting of ePROs (Fig. 1).
CT scan of the lung showing the lung metastasis in the right lung measuring 24.1 x 22.9 mm before vemurafenib treatment (a), and 19.4 x 13.1 mm 3 months after the initiation of vemurafenib treatment (b).
cro-0014-0616-g02.jpg
PMC8077504_01_cro-0014-0616-g02.jpg
F2
TNBC are missing, the patient's health insurance initially did not take care of the drug costs and the patient herself paid for the treatment at the beginning. The patient responded promptly, showing a partial remission of the lung metastasis in the CT scan performed 3 months after the initiation of treatment (Fig. 2a, b).